Amgen is the latest big company to cut its workforce, with a recent restructuring that led to about 300 layoffs, the Thousand Oaks-based biotech company said Monday. Amgen has about 24,000 ...
The Federal Trade Commission said the deal would enable Amgen to exploit its size to block ... forced merging pharmaceutical companies to sell off drugs that treat the same types of diseases ...
Amgen Inc.’s $27.8 billion deal to buy Horizon Therapeutics Plc, the largest in the biotechnology company’s history, will be challenged by federal regulators on the grounds it would hamper ...
The Federal Trade Commission sued to block Amgen's $27.8 billion acquisition of Horizon Therapeutics. The FTC argued that the proposed deal would stifle drug competition in the pharmaceutical ...
The FTC wants to block Amgen's acquisition of Horizon even though the two companies' products don't overlap. The agency thinks that Amgen could try to bundle Horizon's products in a way that ...
This is uncomfortable for Amgen and its shareholders as the company announced last December that it would acquire Horizon. Not only that, but the suitor had said it would pay a premium of nearly ...
It ends patent infringement lawsuits that Amgen had brought against Sanofi ... a February announcement that the company would ...
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/ May 15 (Reuters) - The U.S. Federal Trade Commission is expected to ...
Amgen had sought to collect millions in damages from Sanofi because the pharmaceutical company makes a rival drug called ...
Bloomberg Intelligence Senior Litigation Analyst, Jennifer Rie and Bloomberg Antitrust Reporter Leah Nylen discuss the latest with the FTC's suit to block Amgen's deal with Horizon Therapeutics.
Novartis, which is also named in the complaint, is preparing to spin Sandoz off into a standalone company later this year. Amgen's Prolia is used to treat osteoporosis. Xgeva, with the same active ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
